Cytokinetics, Incorporated (CYTK) AI Stock Analysis

Cytokinetics, Incorporated is a late-stage biopharmaceutical company that discovers, develops, and commercializes therapies targeting debilitating diseases through muscle activators and inhibitors. Headquartered in South San Francisco, California, the company specializes in small molecule drug candidates designed to impact muscle function. Its pipeline includes omecamtiv mecarbil, a cardiac myosin activator in Phase III trials for heart failure, and reldesemtiv, a skeletal muscle troponin activator in Phase III evaluation for ALS and SMA. It is also testing aficamten in Phase III trials for symptomatic obstructive hypertrophic cardiomyopathy, alongside early-stage candidates CK-136 and CK-3772271. Cytokinetics maintains a strategic alliance with Astellas Pharma Inc.

Annual revenue grew at a 5-year CAGR of 9.5% from FY2020 to FY2025, though results varied significantly across years. Revenue fell 92.0% in FY2023 to $7.5M before rebounding 145.3% to $18.5M in FY2024 and 376.6% to $88.0M in FY2025. Gross margin improved to 88.5% in FY2025, but operating margin was -695.4% as R&D expense reached $405.9M. Net loss expanded from -$215.3M in FY2021 to -$785.0M in FY2025, yielding an EPS of -$5.52. For the trailing twelve months ended June 30, 2026, revenue stood at $67.7M with EPS of -$7.22, reflecting a quarterly revenue decline of 57.1% year-over-year.

As of June 30, 2026, Cytokinetics held $1.17B in cash and short-term investments against total debt of $1.27B, resulting in net debt of $104.9M. Total assets were $1.92B, and the current ratio was 6.66. The company operates with negative equity, reporting shareholders' equity of -$173.5M. In FY2025, operating cash flow was -$510.0M and free cash flow was -$534.8M, with capital expenditures of $24.8M. Over five years, the share count increased by 57.1%.

CYTK has a market capitalization of $8.61B and an enterprise value of $9.26B. The stock trades at a forward P/E of 117.6x, compared to 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales ratio is 127.3x and EV-to-revenue is 145.2x, whereas the peer median price-to-sales ratio is 4.1x. Over the past year, CYTK rose 5.1%, trailing the S&P 500 (SPY) return of 16.8%. Over five years, the stock gained 67.9% compared to 83.0% for the index.

Wall Street analysts hold 13 Strong Buy, 7 Buy, and 2 Hold ratings on CYTK, with no Sell or Strong Sell ratings. The mean price target is $109.40, representing 76.6% upside from the last close of $61.95. For the current fiscal year ending December 31, 2026, analysts estimate an EPS of -$5.88 on revenue of $152.0M. For FY2027, 17 analysts project revenue of $427.2M and EPS of -$4.46. Cytokinetics beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of Cytokinetics, Incorporated (CYTK). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CYTK income statement, CYTK balance sheet, CYTK key metrics, CYTK analyst forecast, CYTK chart. See the CYTK stock overview for the latest quote and news.